Antibiotic Resistant Infections among COVID-19 Inpatients in U.S. Hospitals

James Baggs, PhD¹, Ashley N. Rose, MPH¹, Natalie L. McCarthy, MPH¹, Hannah Wolford, MSPH¹, Arjun Srinivasan, MD¹, John A. Jernigan, MD, MS¹, Sujan C. Reddy, MD, MSc¹

¹Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States

Corresponding author: James Baggs, PhD

1600 Clifton Road NE MS: H16-2
Atlanta, GA 30333
Email: jbaggs@cdc.gov

Running title: Antibiotic Resistance COVID-19 Patients
Abstract:

We described bacterial/fungal co-infections and antibiotic resistant infections among inpatients diagnosed with COVID-19 and compared findings with inpatients diagnosed with influenza-like-illness. Less than 10% of COVID-19 inpatients had bacterial/fungal co-infection. Longer lengths of stay, critical care stay, and mechanical ventilation contribute to increased incidence of hospital-onset infections among COVID-19 inpatients.

Keywords: COVID-19, Antibiotic Resistance, Epidemiology
Introduction:

Bacterial co-infections are commonly identified among patients with influenza and other viral respiratory infections [1]. However, estimated rates of bacterial co-infections and secondary bacterial infections among inpatients with Novel Coronavirus Disease 2019 (COVID-19) are low, despite findings of frequent antibiotic use among inpatients with COVID-19 [1-5]. Given the frequent use of antibiotics and reports of increases in antibiotic resistant infections among COVID-19 inpatients and during surges of COVID-19 hospitalizations, our objective was to determine the rate of bacterial or fungal co-infections and certain antibiotic resistant infections among inpatients with COVID-19 [6, 7]. Further, we compared these findings with a cohort of inpatients diagnosed with influenza-like-illness (ILI) discharged during 2019.

Methods:

We conducted a retrospective study using adult and pediatric inpatient discharge and microbiology data from U.S. hospitals included in the Premier Healthcare Database Special COVID-19 Release (PHD-SR, release date 10/12/2021) [8]. The PHD-SR contains discharge records for all inpatients discharged from participating acute care, general, non-Federal US hospitals. Inpatient visit records included diagnostic and procedure codes, demographic information, admission and discharge dates, and facility characteristics [9]. Hospitals were limited to those with available microbiology data. Microbiology data included detailed information such as genus and species of bacterial isolates, day and time stamp of specimens, and associated antimicrobial sensitivity testing results [8].

We described demographic and clinical characteristics of inpatients diagnosed with COVID-19 in 2020–2021 or ILI in 2019. To define the cohort of COVID-19 diagnosed inpatients we selected discharges with an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) primary or secondary diagnosis code of B97.29 (other coronavirus as the cause of diseases classified elsewhere) discharged during March–April 2020 and admitted during February–April 2020 or
discharges with a primary or secondary ICD-10-CM code of U07.1 (COVID-19; introduced April 2020) discharged during April 2020–June 2021 [3]. The cohort of inpatients with ILI was defined as inpatients discharged during January–June 2019 with any primary or secondary ICD-10-CM diagnosis code consistent with ILI (Supplemental Appendix Table A1, see https://www.health.mil/Reference-Center/Publications/2015/10/01/Influenza-Like-Illness).

To identify co-infections among the COVID-19 and ILI cohorts, we first identified patients with at least one microbiology specimen collected between 3 days prior to admission and 3 days post discharge. Specimens with a test result of “bacteria identified”, “fungus identified”, or with an antimicrobial sensitivity result were considered positive bacterial or fungal cultures. We retrospectively calculated proportions of inpatients with a positive bacterial or fungal culture among inpatients with ILI and COVID-19. Organisms identified among specimens with a sensitivity result taken from ILI and COVID-19 inpatients were described with frequencies.

In order to examine antibiotic resistance, we further limited specimens to those that yielded an organism of interest and had susceptibility testing results to determine whether the isolate had the resistance phenotype of interest: methicillin-resistant *Staphylococcus aureus* (MRSA), extended spectrum beta-lactamases (ESBLs), carbapenem-resistant Enterobacteriaceae (CRE), vancomycin resistant Enterococcus (VRE), carbapenem-resistant Acinetobacter spp. (CRAB), and carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) [9]. Specimens categorized as surveillance (i.e., cultures labeled as rectal, perirectal, or nasal) and non-incident cases (defined below) were excluded. Specimens collected from blood, bone, cerebrospinal fluid, peritoneal fluid, pleural fluid, and lymph nodes were considered from sterile body sites. Non-sterile specimen body site specimens included urine, sputum, and wounds. Only the first positive specimen for each phenotype was included. Cultures were defined as incident if the inpatient had no prior inpatient culture of the same phenotype in the previous 14 days. For inpatients with more than one positive clinical culture, cultures from a sterile body site were prioritized over those with non-sterile body site specimen sources within 14 days. Clinical cultures were defined as
community-onset (CO) when the culture was taken between the 3 days preceding admission and the first 3 days after admission. Clinical cultures taken on day 4 or later after admission were considered hospital-onset (HO).

We calculated the rates of resistant infections as the number of positive specimens with the resistance phenotype of interest per 10,000 discharges stratified by epidemiology classification (HO/CO). In addition, we compared the rates of infections for each phenotype and epidemiology classification using a multivariable logistic model and adjusting for age group, gender, race/ethnicity for both CO and HO infections. To evaluate whether differences in HO AR infections between ILI and COVID-19 inpatients were driven by higher severity of illness, we further adjusted for length of stay, critical care stay (yes or no), and mechanical ventilation (yes or no) in secondary models. Models account for inter-facility correlation using generalized estimating equations.

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46; 21 C.F.R. part 56; 42 U.S.C. §241(d), 5 U.S.C. §552a, 44 U.S.C. §3501 et seq.). All data were analyzed using the PySpark (Python) on the Data Collation and Integration for Public Health Event Response (DCIPHER) platform and SAS version 9.4 (SAS Institute Inc., Cary, NC). A value of p<0.01 was considered significant.

Results:

A cohort of 142,426 inpatients diagnosed with ILI were identified in 275 hospitals during January–June 2019 and a cohort of 206,465 COVID-19 diagnosed inpatients were identified in 280 hospitals during January 2020–June 2021 (Supplemental Appendix Table A2). On average, inpatients with COVID-19 had longer lengths of stay (LOS) than inpatients with ILI (mean: 8.3 vs. 6.1 days). The proportion of inpatients who spent at least one day in a critical care unit among those diagnosed with COVID-19 was 48.3% compared with 46.4% among inpatients with ILI. Among inpatients with
COVID-19, 13.0% had at least one day of invasive mechanical ventilation compared with 10.2% of inpatients diagnosed with ILI.

The proportion of inpatients with a bacterial or fungal culture obtained was similar for COVID-19 and ILI (56.2% and 60.4%, respectively). The percent of discharges with a positive culture categorized as CO was lower among inpatients with COVID-19 compared with inpatients with ILI (7.0% vs. 10.4%). However, the percent of discharges with a positive culture categorized as HO was higher among inpatients with COVID-19 (4.1% vs. 2.4%). The most common organisms identified among inpatients diagnosed with ILI and COVID-19 were similar while HO sterile specimen sources for inpatients with COVID-19 were more common (Supplemental Appendix Table A3 and Table A4). CO infection rates of MRSA, ESBL, CRE, VRE, CRAB, and CRPA tended to be lower, but HO infection rates were higher among COVID-19 inpatients compared with those diagnosed with ILI across all pathogens (Table 1).

Multivariable logistic models showed significantly lower odds of CO MRSA, CRPA, and CRAB among inpatients diagnosed with COVID-19 compared with inpatients with ILI (Table 1). There was a significantly higher odds of HO MRSA, ESBL, CRE, and CRPA among COVID-19 inpatients compared with ILI. HO models further adjusted for length of stay, critical care stay, and invasive mechanical ventilation did not show an increase in the odds of HO infections (Supplemental Appendix Table A5).

**Discussion:**

Based on our findings, the incidence of CO bacterial and fungal co-infection, including with antibiotic resistant pathogens, among patients admitted with COVID-19 was less than 10% of patients, indicating that empiric antibiotic therapy should not be used to treat COVID-19 patients [10]. Our findings show that COVID-19 inpatients have a higher risk of HO antibiotic resistant infections compared with inpatients diagnosed with ILI. However, when adjusting for LOS, critical care stay, and
receipt of invasive mechanical ventilation during hospitalization, the differences were less marked,
suggesting that these risk factors contribute to higher HO infection rates among COVID-19 inpatients,
consistent with other studies [4, 5]. Increases in HO-ESBL and other HO infections among COVID-19
inpatients may be due to longer hospital stays associated with COVID-19 and high rates of antibiotic
exposure among inpatients with COVID-19 [3]. A small multi-center study found infections caused by
gram-negative organisms increased in frequency with longer hospital stays among inpatients diagnosed
with COVID-19 [4].

We used a large administrative dataset representing information from a diverse sample of
hospital sizes, teaching status, urban/rural locations, and geographic divisions. However, our study had
several limitations: the study did not include hospitals located in the Mountain U.S. census division;
administrative data are collected primarily for billing purposes and adapted for research resulting in
possible misclassification in clinical and facility information, which is most likely non-differential; and
the study did not include molecular diagnostics for identification of potential infections. However, we
defined antibiotic resistant pathogens using previously validated methods for identifying these infections
among electronic healthcare databases [9]. Prior research on the prevalence of antibiotic resistant
infections among inpatients during the COVID-19 pandemic in the U.S. has consisted mostly of single
center or smaller multi-center studies [4, 11].

The pandemic has changed healthcare delivery, antibiotic prescribing patterns, and infection
control practices within U.S. hospitals and community settings [2, 3, 11, 12]. Longer LOS, critical care
stay, and receipt of invasive mechanical ventilation contribute to incidence of HO antibiotic resistant
infections among inpatients with COVID-19. Hospitals should continue to focus on infection control
and antibiotic stewardship measures for patients with COVID-19 to prevent healthcare-associated
infections, including antibiotic resistant pathogens.
Acknowledgements

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Financial Support: This work was funded by salary funds at the U.S. Centers for Disease Control and Prevention. The authors received no other outside funds.

Supplement Sponsorship: This article appears as part of the supplement “Vaccines, Variants, and Vigilance: Strengthening the COVID-19 Public Health Response through Partnerships and Collaborations”, supported by the Infectious Diseases Society of America through Cooperative Agreement NU50CK000574 with the U.S. Centers for Disease Control and Prevention.

Conflicts: All authors report no conflict of interest.
Citations:

1. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020.
2. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infection Control & Hospital Epidemiology 2020: 1-5.
3. Rose AN, Baggs J, Wolford H, et al. Trends in Antibiotic Use in United States Hospitals During the Coronavirus Disease 2019 Pandemic. Open Forum Infectious Diseases 2021; 8(6).
4. Kubin CJ, McConville TH, Dietz D, et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. Open Forum Infectious Diseases 2021; 8(6).
5. Petty LA, Flanders SA, Vaughn VM, et al. Risk Factors and Outcomes Associated with Community-Onset and Hospital-Acquired Co-infection in Patients Hospitalized for COVID-19: A Multi-Hospital Cohort Study. Infection Control & Hospital Epidemiology 2021: 1-28.
6. Gomez-Simmonds A, Annavajhala MK, McConville TH, et al. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. Journal of Antimicrobial Chemotherapy 2020.
7. Perez S, Innes GK, Walters MS, et al. Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69(48): 1827-31.
8. Premier. The Premier Healthcare Database (COVID-19): Data that Informs and Performs Available at: http://offers.premierinc.com/rs/381-NBB-525/images/PHD_COVID-19_White_Paper.pdf Accessed October 12, 2021.
9. Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017. New England Journal of Medicine 2020; 382(14): 1309-19.

10. Pettit NN, Nguyen CT, Lew AK, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infectious Diseases 2021; 21(1): 516.

11. Baker MA, Sands KE, Huang SS, et al. The Impact of COVID-19 on Healthcare-Associated Infections. Clinical Infectious Diseases 2021.

12. King LM, Lovegrove MC, Shehab N, et al. Trends in US Outpatient Antibiotic Prescriptions During the Coronavirus Disease 2019 Pandemic. Clinical Infectious Diseases 2020.
Tables:

Table 1. Antibiotic Resistant Infections among Inpatients diagnosed with COVID-19 Compared with Inpatients diagnosed with ILI.

|                  | ILI\(^1\)                  | COVID-19\(^2\)               | COVID-19 Compared with ILI |
|------------------|-----------------------------|------------------------------|-----------------------------|
|                  | (N=142,426)                 | (N=206,456)                 |                             |
| Frequency (N)    | Rate per 10,000 discharges  | Rate per 10,000 discharges  | Odds Ratio\(^3\)             |
| MRSA             | 451                         | 1,056                       | 1.54                        |
|                  | 31.7                        | 51.2                        | (1.23, 1.94)                | <.0001                      |
| ESBL             | 186                         | 633                         | 2.34                        |
|                  | 13.1                        | 30.7                        | (1.70, 3.23)                | <.0001                      |
| CRE              | 18                          | 88                          | 2.99                        |
|                  | 1.3                         | 4.3                         | (1.35, 6.62)                | 0.0005                      |
| VRE              | 151                         | 265                         | 1.24                        |
|                  | 10.6                        | 12.8                        | (0.95, 1.62)                | 0.0391                      |
| CRPA             | 86                          | 264                         | 2.03                        |
|                  | 6.0                         | 12.8                        | (1.23, 3.33)                | 0.0003                      |
| CRAB             | 24                          | 41                          | 1.02                        |
|                  | 1.7                         | 2.0                         | (0.52, 2.00)                | 0.9455                      |

Hospital-Onset

|                  | Community-Onset             |
|------------------|-----------------------------|
| MRSA             | 1,395                       | 98.0                        |
|                  | 960                         | 46.5                        |
|                  | 0.55                        | (0.48, 0.63)                | <.0001                      |
| ESBL             | 829                         | 58.2                        |
|                  | 1,059                       | 51.3                        |
|                  | 0.99                        | (0.83, 1.19)                | 0.9385                      |
| CRE              | 41                          | 2.9                         |
|                  | 31                          | 1.5                         |
|                  | 0.57                        | (0.27, 1.18)                | 0.0681                      |
| VRE              | 204                         | 14.3                        |
|                  | 204                         | 9.9                         |
|                  | 0.77                        | (0.53, 1.12)                | 0.0666                      |
| CRPA             | 173                         | 12.1                        |
|                  | 86                          | 4.2                         |
|                  | 0.31                        | (0.20, 0.48)                | <.0001                      |
| CRAB             | 40                          | 2.8                         |
|                  | 27                          | 1.3                         |
|                  | 0.45                        | (0.23, 0.86)                | 0.0013                      |

\(^1\)ILI discharges were defined as a hospitalization with a discharge during January–June 2019 and any of the following primary or secondary discharge diagnosis:

1. Acute respiratory infection
2. Influenza
3. Pneumonia
4. Upper respiratory infection

\(^2\)COVID-19 discharges were defined as 
1. Hospitalizations with a discharge diagnosis of COVID-19
2. Inpatient hospitalizations with a discharge diagnosis of COVID-19

\(^3\)Odds ratio computed using a conditional logistic regression model.
secondary ICD-10-CM codes: B97.89, H66.9, H66.90, H66.91, H66.92, H66.93, J00, J01.9, J01.90, J06.9, J09.X, J10.X, J11.X, J12.89, J12.9, J18, J18.1, J18.8, J18.9, J20.9, J40, R05, R50.9.

COVID-19 discharges were defined as hospitalizations with a primary or secondary ICD-10-CM code of U07.1 discharged during April 2020–June 2021 or a primary or secondary ICD-10-CM code of B97.29 discharged during March–April 2020 and admitted during February–April 2020.

Multivariable logistic models adjusted for gender, age group, race, and ethnicity.